Avalo Therapeutics, Inc. (AVTX) — Financial statements
Income statement, balance sheet, and cash flow for Avalo Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.06↓86.6% | 0.44↓77.1% | 2↓89.3% | 18↑234.4% | 5 | |
| Cost of Revenue | 0.00↑100.0% | -0.37↓128.5% | 1↓62.6% | 3↑130.3% | 1 | |
| Gross Profit | 0.06↓92.7% | 0.81↑26.1% | 0.64↓95.6% | 15↑274.1% | 4 | |
| Operating Expenses | ||||||
| R&D Expenses | 50↓3.8% | 52↑277.8% | 14↓56.0% | 31↓47.7% | 60 | |
| General & Administrative Expenses | 22↑36.3% | 16↑60.2% | 10↓50.2% | 21↓10.3% | 23 | |
| Selling & Marketing Expenses | 0.47↓40.4% | 0.79↑2290.9% | 0.03↓56.6% | 0.08↓95.4% | 2 | |
| SG&A Expenses | 23↑32.8% | 17↑67.4% | 10↓50.3% | 21↓16.0% | 25 | |
| Other Expenses | 0.00 | 0.00↓100.0% | 4↑10181.6% | 0.04↓97.5% | 2 | |
| Operating Expenses | 73↑5.3% | 69↑147.6% | 28↓46.2% | 52↓39.5% | 86 | |
| Total Costs & Expenses | 73↑5.8% | 69↑135.5% | 29↓47.2% | 55↓36.6% | 88 | |
| Operating Results | ||||||
| Operating Income | -73↓6.4% | -69↓150.5% | -27↑26.9% | -37↑54.4% | -82 | |
| Depreciation & Amortization | 0.34↑103.6% | 0.17↑7.0% | 0.16↓4.8% | 0.17↓90.0% | 2 | |
| EBITDA | -73↓6.2% | -68↓193.5% | -23↑37.5% | -37↑53.7% | -80 | |
| EBIT | -73↓6.4% | -69↓192.2% | -23↑37.4% | -37↑54.4% | -82 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00↓100.0% | 3↑197.1% | -3↑18.1% | -4↓74.4% | -2 | |
| Interest Income | 0.00↓100.0% | 3 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00↓100.0% | 3↓18.1% | 4↑74.4% | 2 | |
| Non-Operating Income | 0.00 | 0.00↑100.0% | -4 | 0.00 | 0.00 | |
| Other Income / Expenses | -5↓115.4% | 33↑901.6% | -4↑0.3% | -4↓73.8% | -2 | |
| Income Before Tax | -78↓123.0% | -35↓11.1% | -32↑24.3% | -42↑50.8% | -85 | |
| Income Tax Expense | 0.17↑44.7% | 0.11↑714.3% | 0.01↓50.0% | 0.03↑114.3% | -0.20 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -78↓122.8% | -35↓11.4% | -32↑24.3% | -42↑50.6% | -84 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -0.03 | |
| Net Income | -78↓122.8% | -35↓11.4% | -32↑24.3% | -42↑50.6% | -84 | |
| Bottom-Line Net Income | -78↓122.8% | -35↓11.4% | -32↑24.3% | -42↑50.6% | -84 | |
| EPS (Basic) | -5.84↓35.2% | -4.32↑96.2% | -113.58↑89.3% | -1,062.65↑54.4% | -2,330.66 | |
| EPS (Diluted) | -5.84↓79.1% | -3.26↑97.1% | -113.58↑89.3% | -1,062.65↑54.4% | -2,330.66 | |
| Weighted Average Shares | 13↑64.9% | 8↑2826.8% | 0.28↑608.5% | 0.04↑8.3% | 0.04 | |
| Weighted Average Diluted Shares | 13↑24.3% | 11↑3783.0% | 0.28↑608.5% | 0.04↑8.3% | 0.04 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.